Unknown

Dataset Information

0

Safety and Proof-of-Concept Study of Oral QLT091001 in Retinitis Pigmentosa Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT).


ABSTRACT: UNLABELLED:Restoring vision in inherited retinal degenerations remains an unmet medical need. In mice exhibiting a genetically engineered block of the visual cycle, vision was recently successfully restored by oral administration of 9-cis-retinyl acetate (QLT091001). Safety and visual outcomes of a once-daily oral dose of 40 mg/m2/day QLT091001 for 7 consecutive days was investigated in an international, multi-center, open-label, proof-of-concept study in 18 patients with RPE65- or LRAT-related retinitis pigmentosa. Eight of 18 patients (44%) showed a ?20% increase and 4 of 18 (22%) showed a ?40% increase in functional retinal area determined from Goldmann visual fields; 12 (67%) and 5 (28%) of 18 patients showed a ?5 and ?10 ETDRS letter score increase of visual acuity, respectively, in one or both eyes at two or more visits within 2 months of treatment. In two patients who underwent fMRI, a significant positive response was measured to stimuli of medium contrast, moving, pattern targets in both left and right hemispheres of the occipital cortex. There were no serious adverse events. Treatment-related adverse events were transient and the most common included headache, photophobia, nausea, vomiting, and minor biochemical abnormalities. Measuring the outer segment length of the photoreceptor layer with high-definition optical coherence tomography was highly predictive of treatment responses with responders having a significantly larger baseline outer segment thickness (11.7 ± 4.8 ?m, mean ± 95% CI) than non-responders (3.5 ± 1.2 ?m). This structure-function relationship suggests that treatment with QLT091001 is more likely to be efficacious if there is sufficient photoreceptor integrity. TRIAL REGISTRATION:ClinicalTrials.gov NCT01014052.

SUBMITTER: Scholl HP 

PROVIDER: S-EPMC4687523 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Unlabelled</h4>Restoring vision in inherited retinal degenerations remains an unmet medical need. In mice exhibiting a genetically engineered block of the visual cycle, vision was recently successfully restored by oral administration of 9-cis-retinyl acetate (QLT091001). Safety and visual outcomes of a once-daily oral dose of 40 mg/m2/day QLT091001 for 7 consecutive days was investigated in an international, multi-center, open-label, proof-of-concept study in 18 patients with RPE65- or LRAT-  ...[more]

Similar Datasets

| S-EPMC1132424 | biostudies-other
| S-EPMC2881799 | biostudies-literature
| S-EPMC5503676 | biostudies-literature
| S-EPMC3390653 | biostudies-literature
| S-EPMC2937952 | biostudies-literature
| S-EPMC2486431 | biostudies-literature
| S-EPMC7484280 | biostudies-literature
| S-EPMC8975950 | biostudies-literature
| S-EPMC5555363 | biostudies-literature
| S-EPMC6033202 | biostudies-literature